A startling investigation has revealed a troubling story behind donanemab's approval -- one of questionable data, potential ...

A report published Wednesday in The BMJ questioned the safety and effectiveness of the Alzheimer’s disease drug Kisunla ...

An investigation, published in the journal The BMJ, found that the newly U.S. Food & Drug Administration-approved donanemab is linked ...

The safety and effectiveness of donanemab—an Alzheimer's drug recently approved by the US Food & Drug Administration (FDA)—is ...

The FDA-approved Alzheimer’s drug donanemab is under scrutiny due to concerns about its effectiveness and safety, according ...

The safety and effectiveness of donanemab - an Alzheimer's drug recently approved by the US Food & Drug Administration (FDA) ...

A new drug for Alzheimer’s disease is causing excitement despite excess deaths, missing safety data, questionable efficacy, and financial conflicts of interest among the “independent” advisory ...

Japan's health ministry has officially approved the domestic production and sale of a new drug for Alzheimer's disease.

A “game-changing” new Alzheimer’s treatment was approved for use in the US by “independent” scientists who had received ...

Eli Lilly's Kisunla (donanemab) has been approved in Japan for early symptomatic Alzheimer's, including mild cognitive ...

The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks ...

On Tuesday, The Ministry of Health, Labour and Welfare Japan approved Eli Lilly And Co’s (NYSE:LLY) Kisunla (donanemab) for adults with early symptomatic Alzheimer’s disease (AD), which ...